Cardiovascular disease remains the leading cause of death in the UK, and obesity is a significant contributing risk factor. As Mounjaro (tirzepatide) gains wider use for both diabetes and weight management, researchers are investigating its potential cardiovascular benefits.
What the Research Shows
The SURMOUNT and SURPASS trial programmes have provided encouraging data on cardiovascular risk markers. Patients treated with tirzepatide demonstrated improvements across multiple cardiometabolic parameters:
- Blood pressure reductions — systolic blood pressure decreased by an average of 6-9 mmHg in clinical trials
- Improved lipid profiles — reductions in triglycerides and increases in HDL cholesterol
- Reduced waist circumference — a key marker of visceral fat, which is closely linked to cardiovascular risk
- Lower inflammatory markers — including C-reactive protein (CRP)
The SURPASS-CVOT Trial
Eli Lilly is conducting the SURPASS-CVOT (Cardiovascular Outcomes Trial) to directly assess whether tirzepatide reduces major adverse cardiovascular events (MACE) in patients with type 2 diabetes. This trial is expected to provide definitive evidence on cardiac outcomes and is being closely watched by cardiologists and endocrinologists worldwide.
How This Relates to UK Patients
The British Heart Foundation notes that approximately 7.6 million people in the UK live with heart or circulatory disease. For patients who are overweight or obese with existing cardiovascular risk factors, treatments that address multiple risks simultaneously are particularly valuable.
The NHS currently considers cardiovascular risk as part of the overall assessment when prescribing weight management medications. If you have existing heart conditions or risk factors, your prescriber will take these into account when evaluating whether Mounjaro is appropriate for you.
Important Considerations
While the data is promising, patients should be aware of several important points:
- Mounjaro can cause an increase in heart rate of approximately 2-4 beats per minute on average
- Patients with a history of heart failure should discuss risks carefully with their cardiologist
- Rapid weight loss can occasionally affect cardiac rhythm, so gradual dose titration is important
- Blood pressure medications may need adjusting as weight decreases
Speak to Your Healthcare Team
If you are considering Mounjaro and have cardiovascular concerns, your GP or cardiologist can help weigh the potential benefits against any risks specific to your situation. The combination of weight reduction, improved metabolic markers, and potential direct cardiovascular benefits makes tirzepatide a treatment of considerable interest in UK cardiology circles.